Anti-Thrombotic Effects of Statins in Acute Coronary Syndromes: At the Intersection of Thrombosis, Inflammation, and Platelet-Leukocyte Interactions
Eric L. Wallace,
Susan S. Smyth.
HMG CoA reductase inhibitors, or statins, are standard of care for preventing
cardiovascular disease in at-risk populations. Statins are a well-established
therapy proven to reduce long-term cardiovascular mortality and morbidity for
prevention of secondary cardiovascular events and have become guidelinerecommended
therapy following acute myocardial infarction. Emerging data from
clinical trials over the last decade indicates that statin therapy may provide broad
beneficial effects beyond their primary lipid lowering mechanisms. In coronary
heart disease, statins have demonstrated a unique ability to target several cellular
pathways, which appear to play an underappreciated role in acute inflammation
and subsequent thrombosis. Herein, we review the potential mechanisms where
statins may act as antithrombotic agents in the setting of acute coronary syndromes and discuss the
clinical implications of these findings.
Keywords: Statin, anti-thrombotic, thrombosis, inflammation, platelets.
Rights & PermissionsPrintExport